Trial Profile
A Randomised phase III clinical trial of combined therapy with CPT-11/CDDP versus CPT-11 alone in patients with advanced or recurrent gastric cancer resistant to S-1.
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 13 May 2020
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Irinotecan (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- Acronyms TRICS
- 04 May 2020 Results (n=163) of exploratory analysis comparing efficacy and safety of IRI-based chemotherapy between subgroups progressive disease and early relapse for second-line advanced gastric cancer were published in the European Journal of Cancer
- 20 Jan 2018 Results of an exploratory subgroup analysis from early relapse patients presented at the 2018 Gastrointestinal Cancers Symposium
- 26 Jan 2013 Results presented at the 2013 Gastrointestinal Cancers Symposium.